Search - tctmd.com

Displaying 1 - 20 of 256

Sort: Relevancy | Date

News Conference News ACC 2026

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

Michael O'Riordan

April 01, 2026

News Conference News ACC 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Michael O'Riordan

March 29, 2026

News Conference News ACC 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Yael L. Maxwell

March 28, 2026

News Daily News

Lower LDL Levels, Starting Earlier in Life: New ACC/AHA Dyslipidemia Guidelines

Michael O'Riordan

March 13, 2026

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

Better LDL Control After STEMI Means Less Neoatherosclerosis

Yael L. Maxwell

December 23, 2025

News Daily News

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Yael L. Maxwell

December 15, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2025

Caitlin E. Cox

December 01, 2025

News Conference News AHA 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Michael O'Riordan

November 10, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Todd Neale

November 08, 2025

News Daily News

Evolocumab Wins for Primary Prevention in VESALIUS-CV

L.A. McKeown

October 03, 2025

News Opinion CV Team Dispatch

September 2025 Dispatch for the CV Team

L.A. McKeown

September 30, 2025

News Daily News

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

L.A. McKeown

September 22, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

Advertisement

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Lower LDL Levels, Starting Earlier in Life: New ACC/AHA Dyslipidemia Guidelines

Year in Review: Top Prevention Stories of 2025

Better LDL Control After STEMI Means Less Neoatherosclerosis

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

TCTMD’s Top 10 Most Popular Stories for November 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Evolocumab Wins for Primary Prevention in VESALIUS-CV

September 2025 Dispatch for the CV Team

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

Evolocumab Gains Expanded Indication for Primary Prevention

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content